Share Price and Basic Stock Data
Last Updated: December 10, 2025, 9:51 pm
| PEG Ratio | 1.03 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Orchid Pharma Ltd operates in the competitive pharmaceuticals sector, where it has demonstrated a mixed performance in recent quarters. The company reported a notable revenue of ₹666 Cr for FY 2023, up from ₹560 Cr the previous year. However, the quarterly revenue figures reveal a somewhat volatile trend. For instance, sales peaked at ₹210 Cr in March 2023 but dipped to ₹183 Cr by June 2023, only to rebound to ₹199 Cr in September. This fluctuation signals that while Orchid is capable of generating significant sales, it faces challenges in maintaining consistent growth. The latest figures for FY 2025 indicate a potential increase to ₹922 Cr, which could reflect improved operational strategies or market conditions. Yet, the company’s overall revenue trajectory remains to be seen, especially as it navigates regulatory and competitive pressures.
Profitability and Efficiency Metrics
Profitability metrics for Orchid Pharma present a mixed picture. The operating profit margin (OPM) stood at 13% for FY 2025, a slight decline from 14% the previous year, indicating potential pressures on operational efficiency. Notably, the net profit for FY 2025 was recorded at ₹100 Cr, a significant improvement from the breakeven point of the previous year. Despite these gains, the company’s price-to-earnings (P/E) ratio of 81.4 suggests that investors may be pricing in high future growth expectations, which could be seen as stretched given the current profitability levels. Additionally, the interest coverage ratio (ICR) of 9.95x reflects a comfortable ability to meet interest obligations, although it’s important to monitor how rising costs or market conditions might impact future profitability.
Balance Sheet Strength and Financial Ratios
Orchid Pharma’s balance sheet exhibits a considerable level of strength, with total borrowings reported at ₹282 Cr against reserves of ₹1,223 Cr. This provides a solid buffer for the company, particularly in a capital-intensive industry like pharmaceuticals. The current ratio of 2.83 indicates that Orchid has ample liquidity to cover its short-term liabilities, which is a reassuring sign for investors. However, the price-to-book value (P/BV) ratio of 3.11x may suggest that the stock is trading at a premium compared to its net assets. While this could reflect investor confidence, it also raises questions about valuation sustainability if the company fails to deliver consistent earnings growth. Overall, the financial ratios indicate a firm that is managing its resources reasonably well, albeit with some caution warranted around high valuations.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Orchid Pharma reveals a significant concentration of ownership among promoters, who hold 69.84% of the shares. This stability can often be viewed positively, as it indicates a strong commitment from the founding members. However, the recent decline from a high of nearly 90% in late 2022 may raise questions about insider confidence. On the other hand, the presence of domestic institutional investors (DIIs) has been increasing, now standing at 19.04%, which suggests a growing institutional interest in the stock. This could enhance liquidity and provide a support base for the share price. Yet, with foreign institutional investors (FIIs) holding only 1.56%, the stock might be perceived as less attractive to international markets, which could limit broader investor confidence.
Outlook, Risks, and Final Insight
Looking ahead, Orchid Pharma faces both opportunities and challenges. While the increase in revenue and net profit signals a positive trajectory, the volatility in quarterly sales and declining profit margins present risks that investors should closely monitor. The reliance on a concentrated promoter stake could lead to potential governance issues if not managed transparently. Moreover, the pharmaceutical industry is subject to stringent regulatory scrutiny and competitive pressures, which could impact future growth. Investors should weigh these risks against the company’s financial stability and potential for growth. In this context, a careful assessment of Orchid Pharma’s operational strategies and market positioning will be crucial for making informed investment decisions. Overall, while the stock may offer some upside potential, it also poses inherent risks that demand a cautious approach.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Orchid Pharma Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 142 Cr. | 113 | 244/84.3 | 31.4 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.36 Cr. | 1.76 | 4.33/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,169 Cr. | 383 | 479/192 | 86.3 | 24.3 | 0.17 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 32.4 Cr. | 43.6 | 92.2/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 45.3 Cr. | 30.9 | 31.0/17.0 | 108 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,300.20 Cr | 1,152.20 | 52.34 | 202.18 | 0.36% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 131 | 165 | 160 | 210 | 183 | 199 | 221 | 217 | 244 | 223 | 217 | 237 | 173 |
| Expenses | 119 | 147 | 146 | 170 | 161 | 175 | 185 | 188 | 212 | 192 | 191 | 209 | 159 |
| Operating Profit | 12 | 18 | 14 | 40 | 22 | 23 | 35 | 29 | 32 | 30 | 26 | 28 | 14 |
| OPM % | 10% | 11% | 9% | 19% | 12% | 12% | 16% | 13% | 13% | 14% | 12% | 12% | 8% |
| Other Income | 3 | 6 | 9 | 34 | 2 | 8 | 8 | 13 | 8 | 8 | 8 | 4 | 11 |
| Interest | 8 | 9 | 8 | 7 | 6 | 4 | 4 | 3 | 4 | 3 | 4 | 4 | 3 |
| Depreciation | 22 | 18 | 8 | 7 | 8 | 8 | 9 | 8 | 8 | 9 | 9 | 9 | 9 |
| Profit before tax | -14 | -3 | 7 | 59 | 11 | 20 | 30 | 30 | 28 | 26 | 22 | 19 | 14 |
| Tax % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | -10% | -1% | 0% | 0% | -0% | 0% |
| Net Profit | -15 | -5 | 8 | 59 | 9 | 20 | 29 | 33 | 29 | 27 | 21 | 22 | 15 |
| EPS in Rs | -3.68 | -1.32 | 1.86 | 14.49 | 1.85 | 3.90 | 5.80 | 6.50 | 5.79 | 5.37 | 4.10 | 4.39 | 2.94 |
Last Updated: August 20, 2025, 5:55 am
Below is a detailed analysis of the quarterly data for Orchid Pharma Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 173.00 Cr.. The value appears to be declining and may need further review. It has decreased from 237.00 Cr. (Mar 2025) to 173.00 Cr., marking a decrease of 64.00 Cr..
- For Expenses, as of Jun 2025, the value is 159.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 209.00 Cr. (Mar 2025) to 159.00 Cr., marking a decrease of 50.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 14.00 Cr.. The value appears to be declining and may need further review. It has decreased from 28.00 Cr. (Mar 2025) to 14.00 Cr., marking a decrease of 14.00 Cr..
- For OPM %, as of Jun 2025, the value is 8.00%. The value appears to be declining and may need further review. It has decreased from 12.00% (Mar 2025) to 8.00%, marking a decrease of 4.00%.
- For Other Income, as of Jun 2025, the value is 11.00 Cr.. The value appears strong and on an upward trend. It has increased from 4.00 Cr. (Mar 2025) to 11.00 Cr., marking an increase of 7.00 Cr..
- For Interest, as of Jun 2025, the value is 3.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 4.00 Cr. (Mar 2025) to 3.00 Cr., marking a decrease of 1.00 Cr..
- For Depreciation, as of Jun 2025, the value is 9.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 9.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 14.00 Cr.. The value appears to be declining and may need further review. It has decreased from 19.00 Cr. (Mar 2025) to 14.00 Cr., marking a decrease of 5.00 Cr..
- For Tax %, as of Jun 2025, the value is 0.00%. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00%.
- For Net Profit, as of Jun 2025, the value is 15.00 Cr.. The value appears to be declining and may need further review. It has decreased from 22.00 Cr. (Mar 2025) to 15.00 Cr., marking a decrease of 7.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is 2.94. The value appears to be declining and may need further review. It has decreased from 4.39 (Mar 2025) to 2.94, marking a decrease of 1.45.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 4:43 am
| Metric | Sep 2013n n 18m | Mar 2015n n 18m | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,948 | 1,747 | 873 | 797 | 683 | 600 | 484 | 450 | 560 | 666 | 819 | 922 | 850 |
| Expenses | 1,837 | 1,429 | 703 | 794 | 659 | 612 | 515 | 421 | 505 | 581 | 708 | 804 | 752 |
| Operating Profit | 110 | 317 | 171 | 3 | 24 | -12 | -31 | 29 | 55 | 84 | 111 | 118 | 99 |
| OPM % | 6% | 18% | 20% | 0% | 4% | -2% | -6% | 7% | 10% | 13% | 14% | 13% | 12% |
| Other Income | 92 | 156 | -28 | -59 | 20 | 218 | 24 | 15 | 67 | 52 | 31 | 27 | 31 |
| Interest | 523 | 537 | 294 | 347 | 310 | 7 | 6 | 52 | 33 | 33 | 17 | 15 | 14 |
| Depreciation | 252 | 325 | 145 | 141 | 133 | 130 | 118 | 109 | 87 | 55 | 33 | 35 | 35 |
| Profit before tax | -573 | -389 | -296 | -544 | -399 | 69 | -131 | -117 | 2 | 48 | 92 | 96 | 81 |
| Tax % | -2% | -49% | -6% | -9% | -12% | 0% | 0% | 0% | 0% | 0% | -3% | -0% | |
| Net Profit | -560 | -197 | -279 | -495 | -353 | 69 | -131 | -117 | -2 | 46 | 92 | 100 | 85 |
| EPS in Rs | -79.21 | -23.06 | -31.37 | -55.69 | -39.65 | 7.80 | -32.11 | -28.55 | -0.48 | 11.35 | 18.17 | 19.65 | 16.80 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -77.42% | 28.69% | 119.55% | -289.86% | 10.69% | 98.29% | 2400.00% | 100.00% | 8.70% |
| Change in YoY Net Profit Growth (%) | 0.00% | 106.11% | 90.86% | -409.40% | 300.54% | 87.60% | 2301.71% | -2300.00% | -91.30% |
Orchid Pharma Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 9 years from 2016-2017 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | -6% |
| 5 Years: | 14% |
| 3 Years: | 18% |
| TTM: | -3% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 9% |
| 5 Years: | 23% |
| 3 Years: | 249% |
| TTM: | -24% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 30% |
| 5 Years: | % |
| 3 Years: | 33% |
| 1 Year: | -51% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 2% |
| 3 Years: | 7% |
| Last Year: | 8% |
Last Updated: September 5, 2025, 11:55 am
Balance Sheet
Last Updated: December 4, 2025, 1:45 am
| Month | Sep 2013 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 70 | 85 | 89 | 89 | 89 | 89 | 41 | 41 | 41 | 41 | 51 | 51 | 51 |
| Reserves | 310 | 244 | -40 | -556 | -881 | -793 | 725 | 612 | 607 | 648 | 1,119 | 1,217 | 1,223 |
| Borrowings | 3,204 | 3,211 | 3,215 | 3,106 | 3,202 | 3,230 | 566 | 453 | 268 | 331 | 135 | 175 | 282 |
| Other Liabilities | 1,067 | 521 | 598 | 616 | 715 | 551 | 128 | 132 | 195 | 205 | 249 | 246 | 167 |
| Total Liabilities | 4,651 | 4,061 | 3,862 | 3,256 | 3,125 | 3,077 | 1,460 | 1,237 | 1,111 | 1,225 | 1,554 | 1,688 | 1,722 |
| Fixed Assets | 2,584 | 1,795 | 1,637 | 1,497 | 1,386 | 1,256 | 858 | 670 | 584 | 573 | 620 | 633 | 631 |
| CWIP | 360 | 282 | 280 | 288 | 272 | 278 | 26 | 7 | 10 | 46 | 31 | 81 | 120 |
| Investments | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 15 | 45 | 44 | 46 | 50 | 49 |
| Other Assets | 1,706 | 1,984 | 1,944 | 1,470 | 1,467 | 1,542 | 576 | 544 | 472 | 561 | 857 | 925 | 922 |
| Total Assets | 4,651 | 4,061 | 3,862 | 3,256 | 3,125 | 3,077 | 1,460 | 1,237 | 1,111 | 1,225 | 1,554 | 1,688 | 1,722 |
Below is a detailed analysis of the balance sheet data for Orchid Pharma Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 51.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 51.00 Cr..
- For Reserves, as of Sep 2025, the value is 1,223.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,217.00 Cr. (Mar 2025) to 1,223.00 Cr., marking an increase of 6.00 Cr..
- For Borrowings, as of Sep 2025, the value is 282.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 175.00 Cr. (Mar 2025) to 282.00 Cr., marking an increase of 107.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 167.00 Cr.. The value appears to be improving (decreasing). It has decreased from 246.00 Cr. (Mar 2025) to 167.00 Cr., marking a decrease of 79.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 1,722.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,688.00 Cr. (Mar 2025) to 1,722.00 Cr., marking an increase of 34.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 631.00 Cr.. The value appears to be declining and may need further review. It has decreased from 633.00 Cr. (Mar 2025) to 631.00 Cr., marking a decrease of 2.00 Cr..
- For CWIP, as of Sep 2025, the value is 120.00 Cr.. The value appears strong and on an upward trend. It has increased from 81.00 Cr. (Mar 2025) to 120.00 Cr., marking an increase of 39.00 Cr..
- For Investments, as of Sep 2025, the value is 49.00 Cr.. The value appears to be declining and may need further review. It has decreased from 50.00 Cr. (Mar 2025) to 49.00 Cr., marking a decrease of 1.00 Cr..
- For Other Assets, as of Sep 2025, the value is 922.00 Cr.. The value appears to be declining and may need further review. It has decreased from 925.00 Cr. (Mar 2025) to 922.00 Cr., marking a decrease of 3.00 Cr..
- For Total Assets, as of Sep 2025, the value is 1,722.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,688.00 Cr. (Mar 2025) to 1,722.00 Cr., marking an increase of 34.00 Cr..
Notably, the Reserves (1,223.00 Cr.) exceed the Borrowings (282.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2015n n 18m | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2013n n 18m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 317.00 | 168.00 | 0.00 | 21.00 | -15.00 | -597.00 | -424.00 | -213.00 | -247.00 | -24.00 | -57.00 | 110.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Sep 2013 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 34 | 54 | 130 | 75 | 64 | 73 | 51 | 110 | 111 | 118 | 87 | 96 |
| Inventory Days | 187 | 118 | 220 | 196 | 202 | 214 | 254 | 244 | 201 | 217 | 199 | 219 |
| Days Payable | 220 | 146 | 341 | 402 | 374 | 381 | 182 | 176 | 195 | 165 | 173 | 149 |
| Cash Conversion Cycle | -0 | 26 | 9 | -130 | -108 | -94 | 123 | 179 | 117 | 170 | 113 | 166 |
| Working Capital Days | -399 | -49 | -168 | -500 | -876 | -1,158 | 166 | 302 | 97 | 54 | 118 | 135 |
| ROCE % | -3% | 1% | 1% | -4% | -4% | -5% | -6% | -5% | -2% | 5% | 9% | 8% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Quant Small Cap Fund | 3,465,947 | 0.83 | 251.73 | 1,534,919 | 2025-12-07 17:25:17 | 125.81% |
| Invesco India Contra Fund | 990,763 | 0.36 | 71.96 | N/A | N/A | N/A |
| UTI Value Fund | 745,230 | 0.54 | 54.13 | N/A | N/A | N/A |
| Nippon India Pharma Fund | 492,727 | 0.43 | 35.79 | 1,000,000 | 2025-12-08 04:19:42 | -50.73% |
| Invesco India Smallcap Fund | 455,183 | 0.38 | 33.06 | N/A | N/A | N/A |
| Bandhan Small Cap Fund | 294,201 | 0.12 | 21.37 | N/A | N/A | N/A |
| UTI Small Cap Fund | 283,362 | 0.42 | 20.58 | 445,000 | 2025-12-08 01:35:25 | -36.32% |
| Invesco India ELSS Tax Saver Fund | 153,202 | 0.39 | 11.13 | N/A | N/A | N/A |
| Kotak Multicap Fund | 114,308 | 0.04 | 8.3 | N/A | N/A | N/A |
| UTI Healthcare Fund | 100,000 | 0.65 | 7.26 | 100,000 | 2025-04-22 17:25:24 | 0% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 19.65 | 19.06 | 11.35 | -0.48 | -28.55 |
| Diluted EPS (Rs.) | 19.65 | 19.06 | 11.35 | -0.48 | -28.55 |
| Cash EPS (Rs.) | 25.69 | 25.30 | 25.30 | 21.71 | -1.87 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 249.86 | 230.58 | 168.72 | 158.61 | 159.96 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 249.86 | 230.58 | 168.72 | 158.61 | 159.96 |
| Revenue From Operations / Share (Rs.) | 181.77 | 161.55 | 163.14 | 137.09 | 110.26 |
| PBDIT / Share (Rs.) | 28.52 | 27.91 | 25.25 | 15.22 | 15.93 |
| PBIT / Share (Rs.) | 21.71 | 21.35 | 11.82 | -6.10 | -10.76 |
| PBT / Share (Rs.) | 18.84 | 18.13 | 13.54 | -13.94 | -23.34 |
| Net Profit / Share (Rs.) | 18.88 | 18.74 | 11.88 | 0.38 | -28.55 |
| NP After MI And SOA / Share (Rs.) | 19.65 | 18.17 | 11.35 | -0.47 | -28.55 |
| PBDIT Margin (%) | 15.69 | 17.27 | 15.47 | 11.10 | 14.44 |
| PBIT Margin (%) | 11.94 | 13.21 | 7.24 | -4.44 | -9.75 |
| PBT Margin (%) | 10.36 | 11.22 | 8.29 | -10.16 | -21.16 |
| Net Profit Margin (%) | 10.38 | 11.60 | 7.27 | 0.28 | -25.89 |
| NP After MI And SOA Margin (%) | 10.80 | 11.24 | 6.95 | -0.34 | -25.89 |
| Return on Networth / Equity (%) | 7.86 | 7.88 | 6.72 | -0.30 | -17.84 |
| Return on Capital Employeed (%) | 7.85 | 8.37 | 5.65 | -2.86 | -4.00 |
| Return On Assets (%) | 5.90 | 5.93 | 3.78 | -0.17 | -9.41 |
| Long Term Debt / Equity (X) | 0.10 | 0.10 | 0.21 | 0.32 | 0.65 |
| Total Debt / Equity (X) | 0.13 | 0.11 | 0.48 | 0.41 | 0.65 |
| Asset Turnover Ratio (%) | 0.56 | 0.58 | 0.57 | 0.47 | 0.30 |
| Current Ratio (X) | 2.83 | 3.04 | 1.35 | 1.87 | 3.87 |
| Quick Ratio (X) | 1.68 | 2.03 | 0.73 | 1.15 | 2.79 |
| Inventory Turnover Ratio (X) | 3.12 | 2.14 | 2.02 | 2.09 | 1.60 |
| Interest Coverage Ratio (X) | 9.95 | 8.65 | 3.20 | 1.94 | 1.27 |
| Interest Coverage Ratio (Post Tax) (X) | 7.59 | 6.81 | 1.50 | -0.77 | -0.85 |
| Enterprise Value (Cr.) | 3934.97 | 5169.07 | 1869.70 | 1420.30 | 10472.28 |
| EV / Net Operating Revenue (X) | 4.27 | 6.31 | 2.81 | 2.54 | 23.27 |
| EV / EBITDA (X) | 27.20 | 36.52 | 18.14 | 22.86 | 161.10 |
| MarketCap / Net Operating Revenue (X) | 4.27 | 6.47 | 2.36 | 2.07 | 22.36 |
| Price / BV (X) | 3.11 | 4.53 | 2.28 | 1.79 | 15.41 |
| Price / Net Operating Revenue (X) | 4.27 | 6.47 | 2.36 | 2.07 | 22.36 |
| EarningsYield | 0.02 | 0.01 | 0.02 | 0.00 | -0.01 |
After reviewing the key financial ratios for Orchid Pharma Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 19.65. This value is within the healthy range. It has increased from 19.06 (Mar 24) to 19.65, marking an increase of 0.59.
- For Diluted EPS (Rs.), as of Mar 25, the value is 19.65. This value is within the healthy range. It has increased from 19.06 (Mar 24) to 19.65, marking an increase of 0.59.
- For Cash EPS (Rs.), as of Mar 25, the value is 25.69. This value is within the healthy range. It has increased from 25.30 (Mar 24) to 25.69, marking an increase of 0.39.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 249.86. It has increased from 230.58 (Mar 24) to 249.86, marking an increase of 19.28.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 249.86. It has increased from 230.58 (Mar 24) to 249.86, marking an increase of 19.28.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 181.77. It has increased from 161.55 (Mar 24) to 181.77, marking an increase of 20.22.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 28.52. This value is within the healthy range. It has increased from 27.91 (Mar 24) to 28.52, marking an increase of 0.61.
- For PBIT / Share (Rs.), as of Mar 25, the value is 21.71. This value is within the healthy range. It has increased from 21.35 (Mar 24) to 21.71, marking an increase of 0.36.
- For PBT / Share (Rs.), as of Mar 25, the value is 18.84. This value is within the healthy range. It has increased from 18.13 (Mar 24) to 18.84, marking an increase of 0.71.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 18.88. This value is within the healthy range. It has increased from 18.74 (Mar 24) to 18.88, marking an increase of 0.14.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 19.65. This value is within the healthy range. It has increased from 18.17 (Mar 24) to 19.65, marking an increase of 1.48.
- For PBDIT Margin (%), as of Mar 25, the value is 15.69. This value is within the healthy range. It has decreased from 17.27 (Mar 24) to 15.69, marking a decrease of 1.58.
- For PBIT Margin (%), as of Mar 25, the value is 11.94. This value is within the healthy range. It has decreased from 13.21 (Mar 24) to 11.94, marking a decrease of 1.27.
- For PBT Margin (%), as of Mar 25, the value is 10.36. This value is within the healthy range. It has decreased from 11.22 (Mar 24) to 10.36, marking a decrease of 0.86.
- For Net Profit Margin (%), as of Mar 25, the value is 10.38. This value exceeds the healthy maximum of 10. It has decreased from 11.60 (Mar 24) to 10.38, marking a decrease of 1.22.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 10.80. This value is within the healthy range. It has decreased from 11.24 (Mar 24) to 10.80, marking a decrease of 0.44.
- For Return on Networth / Equity (%), as of Mar 25, the value is 7.86. This value is below the healthy minimum of 15. It has decreased from 7.88 (Mar 24) to 7.86, marking a decrease of 0.02.
- For Return on Capital Employeed (%), as of Mar 25, the value is 7.85. This value is below the healthy minimum of 10. It has decreased from 8.37 (Mar 24) to 7.85, marking a decrease of 0.52.
- For Return On Assets (%), as of Mar 25, the value is 5.90. This value is within the healthy range. It has decreased from 5.93 (Mar 24) to 5.90, marking a decrease of 0.03.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.10. This value is below the healthy minimum of 0.2. There is no change compared to the previous period (Mar 24) which recorded 0.10.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.13. This value is within the healthy range. It has increased from 0.11 (Mar 24) to 0.13, marking an increase of 0.02.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.56. It has decreased from 0.58 (Mar 24) to 0.56, marking a decrease of 0.02.
- For Current Ratio (X), as of Mar 25, the value is 2.83. This value is within the healthy range. It has decreased from 3.04 (Mar 24) to 2.83, marking a decrease of 0.21.
- For Quick Ratio (X), as of Mar 25, the value is 1.68. This value is within the healthy range. It has decreased from 2.03 (Mar 24) to 1.68, marking a decrease of 0.35.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 3.12. This value is below the healthy minimum of 4. It has increased from 2.14 (Mar 24) to 3.12, marking an increase of 0.98.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 9.95. This value is within the healthy range. It has increased from 8.65 (Mar 24) to 9.95, marking an increase of 1.30.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 7.59. This value is within the healthy range. It has increased from 6.81 (Mar 24) to 7.59, marking an increase of 0.78.
- For Enterprise Value (Cr.), as of Mar 25, the value is 3,934.97. It has decreased from 5,169.07 (Mar 24) to 3,934.97, marking a decrease of 1,234.10.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 4.27. This value exceeds the healthy maximum of 3. It has decreased from 6.31 (Mar 24) to 4.27, marking a decrease of 2.04.
- For EV / EBITDA (X), as of Mar 25, the value is 27.20. This value exceeds the healthy maximum of 15. It has decreased from 36.52 (Mar 24) to 27.20, marking a decrease of 9.32.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 4.27. This value exceeds the healthy maximum of 3. It has decreased from 6.47 (Mar 24) to 4.27, marking a decrease of 2.20.
- For Price / BV (X), as of Mar 25, the value is 3.11. This value exceeds the healthy maximum of 3. It has decreased from 4.53 (Mar 24) to 3.11, marking a decrease of 1.42.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 4.27. This value exceeds the healthy maximum of 3. It has decreased from 6.47 (Mar 24) to 4.27, marking a decrease of 2.20.
- For EarningsYield, as of Mar 25, the value is 0.02. This value is below the healthy minimum of 5. It has increased from 0.01 (Mar 24) to 0.02, marking an increase of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Orchid Pharma Ltd:
- Net Profit Margin: 10.38%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 7.85% (Industry Average ROCE: 16.15%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 7.86% (Industry Average ROE: 14.71%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 7.59
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.68
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 80.9 (Industry average Stock P/E: 43.06)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.13
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 10.38%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Plot Nos. 121-128, 128A-133, 138-151, 159-164, SIDCO Industrial Estate, Alathur, Chengalpattu Tamil Nadu 600110 | corporate@orchidpharma.com http://www.orchidpharma.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Ram Gopal Agarwal | Chairman & Non-Exe.Director |
| Mr. Manish Dhanuka | Managing Director |
| Mr. Mridul Dhanuka | Whole Time Director |
| Mr. Arjun Dhanuka | Non Executive Director |
| Mrs. Tanu Singla | Independent Woman Director |
| Dr. Dharam Vir | Independent Director |
| Dr. Manoj Kumar Goyal | Independent Director |
| Ms. Shubha Singh | Independent Woman Director |
FAQ
What is the intrinsic value of Orchid Pharma Ltd?
Orchid Pharma Ltd's intrinsic value (as of 10 December 2025) is 1360.37 which is 63.31% higher the current market price of 833.00, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's 4,226 Cr. market cap, FY2025-2026 high/low of 1,998/604, reserves of ₹1,223 Cr, and liabilities of 1,722 Cr.
What is the Market Cap of Orchid Pharma Ltd?
The Market Cap of Orchid Pharma Ltd is 4,226 Cr..
What is the current Stock Price of Orchid Pharma Ltd as on 10 December 2025?
The current stock price of Orchid Pharma Ltd as on 10 December 2025 is 833.
What is the High / Low of Orchid Pharma Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Orchid Pharma Ltd stocks is 1,998/604.
What is the Stock P/E of Orchid Pharma Ltd?
The Stock P/E of Orchid Pharma Ltd is 80.9.
What is the Book Value of Orchid Pharma Ltd?
The Book Value of Orchid Pharma Ltd is 251.
What is the Dividend Yield of Orchid Pharma Ltd?
The Dividend Yield of Orchid Pharma Ltd is 0.00 %.
What is the ROCE of Orchid Pharma Ltd?
The ROCE of Orchid Pharma Ltd is 8.07 %.
What is the ROE of Orchid Pharma Ltd?
The ROE of Orchid Pharma Ltd is 8.21 %.
What is the Face Value of Orchid Pharma Ltd?
The Face Value of Orchid Pharma Ltd is 10.0.